Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen    BIIB

BIOGEN (BIIB)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Biogen Idec Inc. : Biogen Sees Positive Results From First Year of MS Treatment Study

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/20/2013 | 01:06pm CET
   By Saabira Chaudhuri 
 

Biogen Idec Inc. (BIIB) said it has seen positive results from the first year of a two-year late-stage study of its investigational candidate for a type of multiple sclerosis.

Biogen said results from its two-year pivotal Phase 3 "Advance" study of Plegridy, its investigational candidate for relapsing-remitting multiple sclerosis dosed once every two weeks or every four weeks, indicate that Plegridy significantly reduced multiple sclerosis disease activity, including relapses, disability progression and brain lesions, compared with placebo at one year.

"These full first-year results provide a more complete picture of Plegridy and its positive effects on the reduction of relapse, disability progression and lesion development," said Peter Calabresi, director at the Johns Hopkins Multiple Sclerosis Center. "These data suggest that, if approved, Plegridy may offer the benefit of a less frequent dosing schedule, which would be a meaningful advance for people living with multiple sclerosis."

Plegridy--also called peginterferon beta-1a--met the primary endpoint of reducing annualized relapse rate at one year by 36% compared with placebo. It also met its secondary endpoint, reducing the proportion of patients who relapsed by 39% compared with placebo. Additionally, it significantly reduced the number of gadolinium-enhancing lesions by 86% compared with placebo.

Biogen described Plegridy as a new molecular entity in which interferon beta-1a is pegylated to extend its half-life and prolong its exposure in the body, enabling study of a less-frequent dosing schedule. The investigational drug candidate is a member of the interferon class of treatments and, if approved, would be a new addition to this class, which often is used as a first-line treatment for multiple sclerosis.

The latest announcement comes after, in January, Biogen said data from a late-stage trial of Plegridy were positive. At the time, Biogen said the study's primary endpoint was met for both the two-week and four-week dose regimens. Results showed that Plegridy also met the secondary endpoints. It noted that with both dose regimens studied the risk-benefit profile of Plegridy appears to be favorable.

Also in January, Biogen reported its fourth-quarter earnings fell 2.7% as the biotechnology company's preparations to launch a new drug for multiple sclerosis increased expenses and masked revenue growth from its existing multiple sclerosis treatment.

Shares closed Tuesday at $175.61 and were inactive in recent premarket trading. The stock has risen 47% in the past 12 months.

Write to Saabira Chaudhuri at [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOGEN
12/15 Germany's Merck in fresh bid to enter U.S. MS pill market
12/14 BIOGEN : Appoints Mark Hernon as SVP, Chief Information Officer
12/07 BIOGEN : to Present at the Guggenheim 5th Annual Healthcare Conference
12/05DJRoche's Breast Cancer Drug Herceptin Faces Biosimilar Competition -Cinco Dias
12/04 BIOGEN : Appoints Mark Hernon as SVP, Chief Information Officer
11/28 BIOGEN : Today's Research Reports on Stocks to Watch: Biogen and Teva Pharmaceut..
11/27DJBIOGEN : Alkermes Join Forces for Multiple Sclerosis Drug
11/21 BIOGEN : Appoints Jeff Capello as Executive Vice President and Chief Financial O..
11/20 BIOGEN : to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference
11/02 BIOGEN : Appoints Chirfi Guindo as Executive Vice President and Head of Global M..
More news
News from SeekingAlpha
12/10 BIOTECH IN 2018 : Will Repatriated Cash Fuel A Feeding Frenzy?
12/07 VALUATION DASHBOARD : Healthcare - Update
12/07 YOUR DAILY PHARMA SCOOP : Gilead's Potential, Celgene CAR-T Candidate, Cellectar..
12/06 Biotech drug pricing should not get substantially worse next year - Mizuho
12/05 Looking For Top Stocks In The Strongest Performing Sectors
Financials ($)
Sales 2017 12 033 M
EBIT 2017 6 342 M
Net income 2017 3 880 M
Debt 2017 3 226 M
Yield 2017 -
P/E ratio 2017 17,69
P/E ratio 2018 15,21
EV / Sales 2017 6,03x
EV / Sales 2018 5,59x
Capitalization 69 352 M
Chart BIOGEN
Duration : Period :
Biogen Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Technical analysis trends BIOGEN
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 358 $
Spread / Average Target 9,3%
EPS Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Alisha A. Alaimo Senior Vice President-US Therapeutic Operations
Jeffrey D. Capello Chief Financial Officer & Executive Vice President
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN25.49%69 352
CSL LIMITED40.24%48 543
ALEXION PHARMACEUTICALS-7.57%25 862
GRIFOLS SA28.81%17 812
BIOMARIN PHARMACEUTICAL7.03%16 336
CHONGQING ZHIFEI BIOLOGICAL PRDCT CO LTD--.--%7 011